|
|
Raising the Bar in ATTR Amyloidosis A Training Set on Diagnosis and Treatment
There is considerable heterogeneity in the clinical manifestations of ATTR amyloidosis, which are often dependent on both genetic and environmental factors. Once a fatal diagnosis with no effective therapies available, research in ATTR amyloidosis is rapidly evolving and new pharmacotherapies that demonstrate improved quality of life and life expectancy for patients have been developed. Despite this progress, treatment options remain limited, underscoring the need to continue to expand the tre... |
|
|
Overcoming Challenges to Recognizing, Diagnosing, and Managing Transthyretin Amyloid Cardiomyopathy
Transthyretin amyloid cardiomyopathy (ATTR-CM), once considered rare, is more prevalent than previously thought. Diagnosing this condition can be a challenge, as early symptoms may be nonspecific and attributable to aging, whereas later more severe symptoms can be mistaken for other cardiovascular conditions such as heart failure or may be confused with other causes of amyloidosis. This can be particularly problematic, as it can delay appropriate treatment.
Advances in noninvasive methods f... |
|